<table border="1" cellpadding="2" cellspacing="1" xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption id="TableI">Table I. Mean and range of total body clearance and half-life of
theophylline related to age and altered physiological states.</caption>
<colgroup align="left">
<col width="156*"></col>
<col width="70*"></col>
<col width="70*"></col>
</colgroup>
<tbody valign="bottom">
<tr><td><content stylecode="bold">Population characteristics</content></td><td><content stylecode="bold">Total body clearance*</content><paragraph><content stylecode="bold">mean (range)††</content></paragraph><paragraph><content stylecode="bold">(mL/kg/min)</content></paragraph></td><td><content stylecode="bold">Half-life</content><paragraph><content stylecode="bold">mean (range)††</content></paragraph><paragraph><content stylecode="bold">(hr)</content></paragraph></td></tr>
<tr><td colspan="3"><content stylecode="bold"><content stylecode="underline">Age</content></content></td></tr>
<tr><td>Premature neonates <paragraph>   postnatal age
3-15 days</paragraph><paragraph>   postnatal age 25-57
days</paragraph></td><td>0.29 (0.09-0.49) <paragraph>0.64 (0.04-1.2) </paragraph></td><td>30 (17-43)<paragraph>20 (9.4-30.6)</paragraph></td></tr>
<tr><td>Term infants <paragraph>   postnatal age 1-2 days</paragraph><paragraph>   postnatal age 3-30 weeks</paragraph></td><td><paragraph>NR†</paragraph><paragraph>NR†</paragraph></td><td><paragraph>25.7 (25-26.5)</paragraph><paragraph>11 (6-29)</paragraph></td></tr>
<tr><td>Children <paragraph>   1-4 years </paragraph><paragraph>   4-12 years </paragraph><paragraph>   13-15
years </paragraph><paragraph>   6-17 years </paragraph></td><td>1.7 (0.5-2.9) <paragraph>1.6 (0.8-2.4) </paragraph><paragraph>0.9 (0.48-1.3) </paragraph><paragraph>1.4 (0.2-2.6) </paragraph></td><td>3.4 (1.2-5.6)<paragraph>NR†</paragraph><paragraph>NR†</paragraph><paragraph>3.7 (1.5-5.9)</paragraph></td></tr>
<tr><td>Adults (16-60 years) <paragraph>   otherwise healthy
non-smoking asthmatics </paragraph></td><td>0.65 (0.27-1.03) </td><td>8.7 (6.1-12.8)</td></tr>
<tr><td>Elderly (&gt;60 years) <paragraph>   non-smokers with
normal cardiac, liver, and renal function </paragraph></td><td>0.41 (0.21-0.61) </td><td>9.8 (1.6-18)</td></tr>
<tr><td colspan="3"><content stylecode="bold"><content stylecode="underline">Concurrent illness or altered physiological state</content></content></td></tr>
<tr><td>Acute pulmonary edema</td><td> 0.33** (0.07-2.45) </td><td>19** (3.1-82)</td></tr>
<tr><td>COPD &gt;60 years, stable non-smoker &gt;1 year </td><td>0.54 (0.44-0.64) </td><td>11 (9.4-12.6) </td></tr>
<tr><td>COPD with cor pulmonale </td><td>0.48 (0.08-0.88) </td><td>NR†</td></tr>
<tr><td>Cystic fibrosis (14-28 years) </td><td>1.25 (0.31-2.2) </td><td>6.0 (1.8-10.2)</td></tr>
<tr><td>Fever associated with acute viral respiratory illness (children
9-15 years) </td><td>NR†</td><td>7.0 (1.0-13)</td></tr>
<tr><td>Liver disease -  cirrhosis <paragraph>                        acute
hepatitis </paragraph><paragraph>                        cholestasis </paragraph></td><td>0.31** (0.1-0.7) <paragraph>0.35 (0.25-0.45) </paragraph><paragraph>0.65 (0.25-1.45) </paragraph></td><td>32** (10-56) <paragraph>19.2 (16.6-21.8) </paragraph><paragraph>14.4 (5.7-31,8)</paragraph></td></tr>
<tr><td>Pregnancy - 1st trimester <paragraph>                   2nd
trimester </paragraph><paragraph>                   3rd
trimester </paragraph></td><td>NR†<paragraph>NR†</paragraph><paragraph>NR†</paragraph></td><td>8.5 (3.1-13.9)<paragraph>8.8 (3.8-13.8)</paragraph><paragraph>13.0 (8.4-17.6)</paragraph></td></tr>
<tr><td>Sepsis with multi- organ failure </td><td>0.47 (0.19-1.9) </td><td>18.8 (6.3-24.1)</td></tr>
<tr><td>Thyroid disease - hypothyroid <paragraph>                           hyperthyroid </paragraph></td><td>0.38 (0.13-0.57) <paragraph>0.8 (0.68-0.97) </paragraph></td><td>11.6 (8.2-25) <paragraph>4.5 (3.7-5.6)</paragraph></td></tr>
<tr><td colspan="3">¶ For various North American patient populations
from literature reports. Different rates of elimination and consequent
dosage requirements have been observed among other peoples.</td></tr>
<tr><td colspan="3">* Clearance represents the volume of blood completely
cleared of theophylline by the liver in one minute. Values listed
were generally determined at serum theophylline concentrations &lt;20
mcg/mL; clearance may decrease and half-life may increase at higher
serum concentrations due to non-linear pharmacokinetics.</td></tr>
<tr><td colspan="3">†† Reported range or estimated range
(mean ± 2 SD) where actual range not reported.</td></tr>
<tr><td colspan="3">† NR = not reported or not reported in a comparable
format.</td></tr>
<tr><td colspan="3">** Median</td></tr>
</tbody>
</table>